

Special Issue

A Personalized Medicine Approach to the Diagnosis and Management of Autism Spectrum Disorder: Biological Targets for Effective Treatments

Message from the Guest Editor

Autism spectrum disorder (ASD) now affects more than 2% of children, and its prevalence continues to increase. The majority of research on ASD focuses on identifying the genetic syndrome, but there is a new understanding that the etiology of ASD is very complex and likely driven by various genetic variations and vulnerabilities that interact with environmental exposures and triggers. Our aim is to publish high-impact articles describing a personalized medicine approach for the diagnosis, classification, and treatment of ASD. This year, we wish to focus on the emerging understanding of the role of environmental factors, their contribution to genetic variants and vulnerabilities, and their interaction with the environment.

We encourage the submission of manuscripts that describe a personalized medicine approach for the diagnosis, classification, and treatment of ASD, particularly those that describe the influence of environmental factors and/or genetic variants.

Guest Editor


Prof. Dr. Richard E. Frye

1. Department of Child Health, College of Medicine—Phoenix, University of Arizona, Phoenix, AZ 85004, USA

2. Section on Neurodevelopmental Disorders, Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, AZ 85016, USA

Deadline for manuscript submissions

closed (20 January 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/205591

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).